Medicine biotechnology company focusing on discovering, developing and deploying psychedelics-inspired medicines to improve mental wellness and cure addiction MindMed Inc. (MNMD) (NEO: MMED) announced having appointed Dr. Bryan L. Roth, a psychiatrist and pharmacologist from University of North Carolina to its scientific advisory board.
Dr. Roth is a coveted professor at the Department of Pharmacology at the University of North Carolina’s (UNC) School of Medicine. He also doubles up as the director of the National Institute of Mental Health Psychoactive Drug Screening Program.
Dr. Roth has conducted studies focusing on eliminating the hallucinogenic effects from psychedelic drugs by removing the hallucinatory trips which may make some patients shy away from psychedelic-assisted therapies.
“Psychedelic compounds like psilocybin have some of the most robust antidepressant effects I’ve ever seen in Phase II studies. But not all patients are comfortable with their treatment program requiring hallucinatory trips. My research, and the perspective I’m excited to bring to MindMed’s drug development programs, focuses on how we can make drugs that are maximally helpful to patients while minimizing discomfort in the treatment process,” says Dr. Roth on his studies.
